George D. Yancopoulos

2021

In 2021, George D. Yancopoulos earned a total compensation of $6.4M as President and Chief Scientific Officer at Regeneron Pharmaceuticals, a 95% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$4,030,584
Salary$1,767,800
Other$599,980
Total$6,398,364

Yancopoulos received $4M in non-equity incentive plan, accounting for 63% of the total pay in 2021.

Yancopoulos also received $1.8M in salary and $600K in other compensation.

Rankings

In 2021, George D. Yancopoulos' compensation ranked 1,987th out of 12,397 executives tracked by ExecPay. In other words, Yancopoulos earned more than 84.0% of executives.

ClassificationRankingPercentile
All
1,987
out of 12,397
84th
Division
Manufacturing
753
out of 5,492
86th
Major group
Chemicals And Allied Products
291
out of 2,367
88th
Industry group
Drugs
250
out of 2,090
88th
Industry
Pharmaceutical Preparations
161
out of 1,537
90th
Source: SEC filing on April 21, 2022.

Yancopoulos' colleagues

We found five more compensation records of executives who worked with George D. Yancopoulos at Regeneron Pharmaceuticals in 2021.

2021

Daniel Van Plew

Regeneron Pharmaceuticals

Executive Vice President and General Manager, Industrial Operations and Product Supply

2021

Robert Landry

Regeneron Pharmaceuticals

Chief Financial Officer

2021

Andrew Murphy

Regeneron Pharmaceuticals

Executive Vice President, Research

2021

Joseph LaRosa

Regeneron Pharmaceuticals

General Counsel

2021

Leonard Schleifer

Regeneron Pharmaceuticals

Chief Executive Officer

News

You may also like